前哨淋巴结活检在乳腺癌新辅助化疗后腋窝状况评估中的价值

目的探讨对于乳腺癌患者采用新辅助化疗后其前哨淋巴结活检的临床价值。方法回顾性分析我院于2009年1月至2012年5月所收治的行亚甲蓝跟踪前哨淋巴结活检术及腋窝淋巴结清扫术的50例乳腺癌患者临床资料,其中27例患者行2~3个疗程的新辅助化疗后再进行前哨淋巴结活检(SLNB)及腋窝淋巴结清扫术,另外23例患者直接做前哨淋巴结活检腋窝淋巴结清扫术。结果新辅助化疗组SLN(前哨淋巴结)数、SLN检出率、SLN假阴性率以及平均腋窝淋巴结数与非新辅助化疗组相比较无明显差异(P>0.05)。结论前哨淋巴结活检对新辅助化疗后的乳腺癌患者能够准确的预测其腋窝淋巴结的状况。

The Value in The Assessment of Axillary Status after Neoadjuvant Chemotherapy Sentinel Lymph Node Biopsy

Objective To investigate the clinical value of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer patients. Methods Retrospective analysis of sentinel lymph node biopsy and axillary lymph node dissection in 50 cases of breast cancer patients with Clinical data admitted to our hospital from January 2009 to May 2012 line of methylene blue track line 2 to 3 of the 27 patients cycles of neoadjuvant chemotherapy after sentinel lymph node biopsy （SLNB） and axillary lymph node dissection, and another 23 patients directly to do sentinel lymph node biopsy axillary lymph node dissection. Results Neoadjuvant chemotherapy group SLN （sentinel lymph node） number, SLN detection rate, SLN false negative rate, and average axillary lymph nodes with neoadjuvant chemotherapy group compared with no significant difference （P〉0.05）. Conclusion Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients to be able to accurately predict the axillary lymph node status